An UPLC-PDA assay for simultaneous determination of seven antibiotics in human plasma

•Simultaneous determination of seven antibiotics with a wide calibration curve range.•Fast turn-around time (4.5 min) allowed for a high throughput analysis.•Successfully applied to clinical pharmacokinetic study in critically ill patients. Appropriate antibiotic dosing in critically ill patients re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical and biomedical analysis 2022-02, Vol.210, p.114558-114558, Article 114558
Hauptverfasser: Xie, Feifan, Liu, Lanyu, Wang, Yan, Peng, Yaru, Li, Sanwang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Simultaneous determination of seven antibiotics with a wide calibration curve range.•Fast turn-around time (4.5 min) allowed for a high throughput analysis.•Successfully applied to clinical pharmacokinetic study in critically ill patients. Appropriate antibiotic dosing in critically ill patients requires concentration monitoring due to the occurrence of pathophysiological changes and frequent extracorporeal therapy that could significantly alter the normal pharmacokinetics of drugs. Herein, we describe an ultra-performance liquid chromatography with photodiode array (UPLC-PDA) for the simultaneous concentration determination of seven frequently used antibiotics (meropenem, cefotaxime, cefoperazone, piperacillin, linezolid, moxifloxacin, and tigecycline) in plasma from critically ill patients. The analytes were extracted from 200 μL human plasma by the addition of methanol for protein precipitation. The chromatographic separation was achieved using an ACQUITY UPLC HSS T3 column (2.1 × 50 mm, 1.8 µm) with a water (containing 0.1% trifluoroacetic acid)/acetonitrile linear gradient at a flow rate of 0.5 mL/min in a 4.5 min turn-around time. PDA detection wavelength was set individually for the analytes. The method was fully validated according to the European Medicines Agency (EMA) guideline. The lower limits of quantification for the analytes were between 0.05 and 0.8 μg/mL. The method is accurate (intra/inter-assay bias −8.4 to +12.4%) and precise (intra/inter-assay coefficient of variations 0.9–10.1%) over the clinically relevant plasma concentration ranges (upper limits of quantification 5–400 µg/mL). The applicability of the method has been successfully demonstrated by analyzing plasma samples collected from critically ill patients undergoing continuous renal replacement therapy.
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2021.114558